A5114928862- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Glioma Diagnosis and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Metabolism and Genetic Disorders
- Ocular Oncology and Treatments
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- Neonatal and fetal brain pathology
- Children's Physical and Motor Development
- Neuroendocrine Tumor Research Advances
- Genetic factors in colorectal cancer
- Neurological and metabolic disorders
- Child Nutrition and Feeding Issues
- Pain Management and Opioid Use
- Central Venous Catheters and Hemodialysis
- Chronic Lymphocytic Leukemia Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Meningioma and schwannoma management
- Cancer Diagnosis and Treatment
- Heme Oxygenase-1 and Carbon Monoxide
- Epilepsy research and treatment
Yamagata Prefectural Shinjo Hospital
2024-2025
Yamagata University
1997-2024
Osaka Medical and Pharmaceutical University
2007-2011
Glioblastoma is a primary brain tumor associated with poor prognosis due to its high chemoresistance capacity. Cancer stem cells (CSCs) are one of the mechanisms chemoresistance. Although therapy targeting CSCs promising, strategies remain unsuccessful. Abnormal activation epidermal growth factor receptors (EGFRs) amplification, mutation, or both EGFR gene common in glioblastomas. However, glioblastomas resistant tyrosine kinase inhibitors (EGFR-TKIs), and overcoming resistance essential....
Background/Aim: Zolbetuximab, a CLAUDIN18.2-targeted antibody, traditionally requires inpatient administration due to potential adverse events. This study evaluated the safety and feasibility of outpatient in community cancer center setting. Patients Methods: Five patients with CLAUDIN18.2-positive advanced gastric received zolbetuximab between July November 2024. We implemented structured protocol incorporating standardized premedication, hospital-pharmacy collaboration, comprehensive...
Background/Aim: Despite advances in treatment modalities, the visual prognosis of retinoblastoma still remains unsatisfactory, underscoring need to develop novel therapeutic approaches. Materials and Methods: The effect on growth six human cell lines a normal fibroblast line CEP1347, small-molecule kinase inhibitor originally developed for Parkinson9s disease therefore with known safety profile humans, was examined. role P53 pathway CEP1347-induced inhibition also investigated. Results:...
The development of pharmacological inhibitors targeting negative regulators p53, such as murine double minute (MDM) 2 and, more recently, MDM4, has been actively pursued a potential strategy to treat cancers with wild-type p53. We previously showed that CEP-1347, small molecule kinase inhibitor originally developed for the treatment Parkinson's disease, suppressed MDM4 expression and activated p53 in retinoblastoma cells. However, it remains unknown whether CEP-1347 acts an activates other...
Glioblastoma (GBM) is one of the deadliest all human cancers. Developing therapies targeting GBM cancer stem cells or glioma (GSCs), which are deemed responsible for malignancy due to their therapy resistance and tumor-initiating capacity, considered key improving dismal prognosis patients. In this study, we found that folate antagonists, such as methotrexate (MTX) pemetrexed, selectively cytotoxic GSCs, but not differentiated counterparts, normal fibroblasts, neural in vitro, high...
Abstract: Background and Objectives: Phyllodes tumors are rare breast neoplasms with limited therapeutic options poorly understood molecular characteristics. This study aimed to analyze genomic alterations treatment outcomes in advanced phyllodes using Japan's national clinical testing registry (C-CAT database) identify potential targets predictive markers. Materials Methods: We conducted a retrospective analysis of 60 tumor cases from 80,329 patients registered the C-CAT database...
: Phyllodes tumors are rare breast neoplasms with limited therapeutic options and poorly understood molecular characteristics. This study aimed to analyze genomic alterations treatment outcomes in advanced phyllodes using Japan's national clinical testing registry (C-CAT database) identify potential targets predictive markers.
Vascular pain associated with NK1 receptor antagonists, particularly fosaprepitant, remains a significant challenge in cancer chemotherapy. The present study investigated the incidence of vascular administration fosaprepitant and fosnetupitant assessed psychological burden on nurses performing venipuncture.
Despite several clinical trials with encouraging findings, effective standard systemic therapies have yet to be established for malignant meningioma and the prognosis of these patients remains poor. Accumulating preclinical evidence suggests that gemcitabine is against meningioma. To identify drugs therapeutic effects may enhanced in combination gemcitabine, we screened been tested In IOMM-Lee HKBMM cells, growth inhibitory mTOR inhibitor everolimus, benefits which demonstrated The...
Mucoepidermoid carcinoma (MEC) is the most common salivary gland carcinoma; however, hepatobiliary MEC extremely rare. A 74-year-old patient was diagnosed with after hepatectomy. We considered its origin could be peribiliary glands. Its genome profile similar to rather than standard biliary tract carcinoma.
Abstract BACKGROUND Although a significant proportion of meningiomas are clinically aggressive, there is currently no effective chemotherapy for them. An increasing number studies have been conducted to develop targeted therapies, but none focused on the p53 pathway as potential target. In this study, we determined in vitro and vivo effects CEP-1347, novel small-molecule inhibitor MDM4 with known safety humans, malignant meningioma cells, also investigated CEP-1347 when combined MDM2...
Background: Epidermal growth factor receptor (EGFR) inhibition is crucial in treating RAS wild-type metastatic colorectal cancer, yet current testing methods may miss rare variants affecting treatment efficacy. Methods/Results: We analyzed 4,122 cancer patients receiving anti-EGFR antibodies from the Center for Cancer Genomics and Advanced Therapeutics database, identifying 54 (1.3%) with undetectable by standard testing. These showed significantly lower response rates to therapy (28.3%)...